Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics, announced today the close of a $92 million Series A financing round ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback